



NextCell's partner PBKM exercises its TO 1 warrants

Stem cell company NextCell Pharma AB ("NXTCL") announces today that its shareholder and partner Polski Bank Komórek Macierzystych S.A. ("PBKM") is exercising all of its 320,000 warrants. This represents an investment of MSEK 1.6, corresponding to approximately 11 % of the outstanding series TO 1 warrants. The subscription period of the series TO 1 warrants runs from 23rd of August – 13th of September 2018.

PBKM is one of Europe's leading players in the field of stem cells and is also contracted for the manufacturing of NXTCL's drug candidate ProTrans. PBKM is thus an important partner of NXTCL and also a major shareholders with a shareholding of approximately 2.4 % of votes and capital before exercising the series TO 1 warrants. In addition to its current shareholdings, PBKM also has 320,000 series TO 1 warrants. Each series TO 1 warrant entitles to the subscription of a new share in NXTCL. A subscription agreement is entered into whereby PBKM exercises all of its warrants which means an investment of MSEK 1.6. Assuming full utilization of all outstanding series TO 1 warrants PBKM will come to hold approximately 4.9 % of votes and capital in NXTCL.

NXTCL's series TO 1 warrants were issued as part of the company's issue of units during May / June 2017 and can contribute approximately SEK 14.3 million to the company before issue costs. Each warrant in the TO 1 series entitles the holder to subscribe for one new share in NXTCL at a subscription price of SEK 5.00 per share. The liquidity gained through the use of the series TO 1 warrants is primarily intended to fund the completion of the phase I / II study with ProTrans and certain pre-clinical activities with ProTrans, with the aim of attracting a partner to conduct clinical trials with.

Mathias Svahn, CEO of NXTCL, comments:

"PBKM's continued investments and dedication to support NXTCL is reassuring. We have a strategic shareholder with great insight in the stem cell field who recognizes our work."

About Polski Bank Komórek Macierzystych S.A.

Polski Bank Komórek Macierzystych S.A. is one of Europe's largest stem cell banks for the family-saving of stem cells. Over 145,000 parents have chosen PBKM to save their stem cells. In addition, PBKM invests in the development of advanced cell therapies. The company was founded in 2002 and is listed on the Warsaw Stock Exchange. During the fiscal year 2017, the PBKM Group reported a turnover of approximately 360 MSEK. In addition to its operations in Poland, PBKM also operates in other countries such as: Hungary, Romania, Spain and Turkey.

Financial adviser and issuing agent

Sedermora Fondkommission is the financial advisor to NXTCL for the subscription period of the series TO 1 warrants.

For more information regarding the subscription of series TO 1 warrants, please contact:

Sedermora Fondkommission

Phone: 040-615 14 10

E-mail: info@sedermora.se

www.sedermora.se

NextCell Pharma AB
Press release 2018-08-17



This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 17th of August 2018.

Stay up to date with the latest development in NextCell Pharma

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Leo Groenewegen, CFO

Phone: 08-735 5595

E-mail: info@nextcellpharma.com

www.nextcellpharma.com

About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.